Scholarlink

<p>Metformin (Met) is a pharmaceutical agent for the treatment of type 2 diabetes mellitus. Intriguingly, it may also play a role in the gastrointestinal tract, the gut microbial communities, and the tissue-resident immune cells. The present study aimed to investigate whether the administration of Met achieved protective effects on high-fat diet (HFD)-fed mice with colorectal adenomas (CRA) and elucidated its mechanism via the gut microbiota. AOM/DSS was administered in an HFD-induced diet to induce CRA in mice. 16&#xa0;S rRNA sequencing was conducted to analyze the gut microbiota profile of mice. Met reduced the inflammatory response in the intestine and alleviated HFD-induced intestinal flora disturbances, and <i>Roseburia intestinalis</i> (<i>R. intestinalis</i>) colonization enhanced the efficacy of Met. Met suppressed CRA cell proliferation, which was further reduced by <i>R. intestinalis</i>. Met blocked NF-κB signaling by activating GILZ through increased <i>R. intestinalis</i> abundance. GILZ deletion in macrophages weakened the inhibition of CRA growth by Met and <i>R. intestinalis</i>, leading to increased macrophage M1 polarization. Inhibition of the NF-κB signaling reversed the activation of macrophage M1 polarization by knockdown of GILZ and reduced the proliferation of CRA cells. Our results shed light on the impact of Met on gut microbiome alteration in treating CRA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Potential Benefits of Metformin Via Roseburia Intestinalis in High-fat Diet-fed Mice With Colorectal Adenomas

  • 期刊论文

  • 发表日期：

    2025年11月26日

查看全文
  • Jiankun Wang,
  • Bangting Wang,
  • Min Wang,
  • Lili Zhao,
  • Li Liu,
  • Zhining Fan

摘要

Metformin (Met) is a pharmaceutical agent for the treatment of type 2 diabetes mellitus. Intriguingly, it may also play a role in the gastrointestinal tract, the gut microbial communities, and the tissue-resident immune cells. The present study aimed to investigate whether the administration of Met achieved protective effects on high-fat diet (HFD)-fed mice with colorectal adenomas (CRA) and elucidated its mechanism via the gut microbiota. AOM/DSS was administered in an HFD-induced diet to induce CRA in mice. 16 S rRNA sequencing was conducted to analyze the gut microbiota profile of mice. Met reduced the inflammatory response in the intestine and alleviated HFD-induced intestinal flora disturbances, and Roseburia intestinalis (R. intestinalis) colonization enhanced the efficacy of Met. Met suppressed CRA cell proliferation, which was further reduced by R. intestinalis. Met blocked NF-κB signaling by activating GILZ through increased R. intestinalis abundance. GILZ deletion in macrophages weakened the inhibition of CRA growth by Met and R. intestinalis, leading to increased macrophage M1 polarization. Inhibition of the NF-κB signaling reversed the activation of macrophage M1 polarization by knockdown of GILZ and reduced the proliferation of CRA cells. Our results shed light on the impact of Met on gut microbiome alteration in treating CRA.